New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) […]
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1 Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients’ historic rapid […]
PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ — RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared […]
ROTTERDAM, Netherlands and SAN DIEGO, Oct. 24, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announced today the results of […]
STOCKHOLM, Oct. 24, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the Clinical Trials for Alzheimer’s […]
